Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOncology: Clinical Therapy & Diagnosis (includes Phase 2, Phase 3, post approval studies) - Endocrine/Neuroendocrine Cancers

Evaluation of [68Ga]Ga-DOTA-CP04 imaging in Cholecystokinin-2 receptors (CCK-2R) positive tumors

Grace Kong, Duncan Sutherland, Peter Roselt, Rodney Hicks, Mohammad Haskali and Tim Akhurst
Journal of Nuclear Medicine June 2023, 64 (supplement 1) P242;
Grace Kong
1Peter MacCallum Cancer Centre
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Duncan Sutherland
2Peter MacCallum Cancer Centre, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Roselt
3Peter MacCallum Cancer Center, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rodney Hicks
4Precision Molecular Imaging and Theranostics
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mohammad Haskali
2Peter MacCallum Cancer Centre, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tim Akhurst
5University of Melbourne Department of Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Article Information

vol. 64 no. supplement 1 P242

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Published online August 28, 2023.

Copyright & Usage 
© 2023

Author Information

  1. Grace Kong1,
  2. Duncan Sutherland2,
  3. Peter Roselt3,
  4. Rodney Hicks4,
  5. Mohammad Haskali2 and
  6. Tim Akhurst5
  1. 1Peter MacCallum Cancer Centre
  2. 2Peter MacCallum Cancer Centre, Australia
  3. 3Peter MacCallum Cancer Center, Australia
  4. 4Precision Molecular Imaging and Theranostics
  5. 5University of Melbourne Department of Medicine

Statistics from Altmetric.com

Cited By...

  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

Article usage

Article usage: August 2023 to April 2025

AbstractFullPdf
Aug 2023400
Sep 20231200
Oct 20231300
Nov 20233000
Dec 20231600
Jan 20242400
Feb 2024500
Mar 2024500
Apr 20245200
May 20242800
Jun 20243300
Jul 20249500
Aug 20248400
Sep 20243400
Oct 20241500
Nov 20241300
Dec 20241700
Jan 20251900
Feb 20252100
Mar 20251500
Apr 20251800
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 64, Issue supplement 1
June 1, 2023
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Evaluation of [68Ga]Ga-DOTA-CP04 imaging in Cholecystokinin-2 receptors (CCK-2R) positive tumors
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Evaluation of [68Ga]Ga-DOTA-CP04 imaging in Cholecystokinin-2 receptors (CCK-2R) positive tumors
Grace Kong, Duncan Sutherland, Peter Roselt, Rodney Hicks, Mohammad Haskali, Tim Akhurst
Journal of Nuclear Medicine Jun 2023, 64 (supplement 1) P242;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Evaluation of [68Ga]Ga-DOTA-CP04 imaging in Cholecystokinin-2 receptors (CCK-2R) positive tumors
Grace Kong, Duncan Sutherland, Peter Roselt, Rodney Hicks, Mohammad Haskali, Tim Akhurst
Journal of Nuclear Medicine Jun 2023, 64 (supplement 1) P242;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • The value of PET/MR in evaluating the amplification of MYCN gene in children with neuroblastoma
  • Comparison of 18F-MFBG PET/CT and MRI in the evaluation of Neuroblastoma
  • Characterizing Early Disease Progression in GEP-NET Patients After Peptide Receptor Radionuclide Therapy (PRRT)
Show more Oncology: Clinical Therapy & Diagnosis (includes Phase 2, Phase 3, post approval studies) - Endocrine/Neuroendocrine Cancers

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire